分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Engineered CAR-monocytes coordinate fibrosis clearance and cardiac regeneration following myocardial infarction

Zhenguo Wu, Xiaohan Zou, Chen Chen, Mengge Zhou, Xiao Yue, Dachuan Guo, Yunqian Gao, Chang Ma, Qingmei Han, Danning Yang, Dejin Zang, Ruicheng Song, Yifei Li, Shujie Pang, Haoran Ren, Wencheng Zhang,

Journal:Cell Stem Cell

IF:23.3

DOI:10.1016/j.stem.2026.04.003

PMID:42034061

Published:2026-04-24

research field:分子生物学免疫治疗心脏病学再生医学细胞工程

Abstract

Overwhelming cardiomyocyte death and excessive cardiac fibrosis post myocardial infarction (MI) collectively lead to heart failure and mortality. For treating this devastating disease, it is essential to eliminate fibrosis and reconstitute the damaged myocardium, yet effective strategies remain elusive. Here, we created pleiotropic chimeric antigen receptor-monocytes (pCAR-Mos), revitalizing the injured heart via synergistic fibrosis clearance and myocardial reconstitution. Specifically, we engineered monocytes to express fibroblast activation protein (FAP)-chimeric antigen receptor (CAR) and secrete the cardioregenerative protein Agrin. CAR-mediated phagocytosis of myofibroblasts, which was further enhanced by Agrin, significantly attenuated fibrotic scar formation. Moreover, Agrin secretion promoted cardiomyocyte regeneration, thereby facilitating replenishment of functional myocardium. Treatment with pCAR-Mos remodeled the cardiac fibrotic microenvironment and substantially restored cardiac function in MI mice. In sum, our findings confirmed that pCAR-Mos exerted potent phagocytic activity against profibrotic myofibroblasts while simultaneously enabling myocardial reconstitution, thereby providing a reversible treatment strategy for MI with broad application in other fibrotic diseases.

本文使用的Yeasen产品

购物车
客服
转染试用